Tomahawk, WI 3/26/2013 (Expedated) – The boys of spring are on the diamonds and the sounds of baseball fill the air. As we head into Tuesday there are a lot of companies out there taking a big swing for the fences and some are striking out. Lets take a look.

Trying to get out of the inning intact, we find  shares of  Ziopharm Oncology Inc. (ZIOP) sinking like a slider down over 60% in morning trading.  It looks like the runner will be thrown out at the plate as the company has just announced that its most advanced product, the potential cancer treatment palifosfamide, failed in a late-stage study.

This news has brought a change in the lineup to Ziopharm’s game and strategy as they have said they immediately plan to switch their strategic focus to synthetic biology programs and start a restructuring program to muster resources for that.

With no products on the market, and having lost more than half their value it could be tough to get out of the inning.

Palifosfamide was being studied as a treatment for patients with soft tissue sarcoma, which is a cancer that forms in connective tissue. Today the company reported that the drug missed its main goal of improvement in progression-free survival, which measures the time before a disease progresses or the patient in the study dies. It said full data from the study will be submitted for scientific journal publication.

Ziopharm will continue to study the drug in mid-stage trials as possible a possible treatment for forms of lung, testicular and ovarian cancers.

Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. They are my opinions only. Trading stocks is risky — always be sure to know and understand your risk tolerance. You can incur substantial financial losses in any trade or investment. Always do your own due diligence before buying and selling any stock, and/or consult with a licensed financial adviser.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.


Please enter your comment!
Please enter your name here